Key Development
The most striking number is not the $2.13 billion headline. It is the $400 million Merck is paying upfront for a molecule that has not yet entered human trials.
On September 28, 2026, Merck entered an exclusive global licensing agreement with China-based SciBrunch Therapeutics for SPR2015, an investigational oral inhibitor targeting active-state KRAS G12D. Merck gains worldwide development, manufacturing and commercialization rights. SciBrunch receives $400 million upfront and can earn development and commercial milestones that bring the total potential transaction value to $2.13 billion.
SPR2015 is described as a molecular-glue KRAS G12D (ON) inhibitor that recruits cyclophilin A to form a complex capable of blocking active KRAS signaling. Preclinical data presented at AACR 2026 showed activity across pancreatic, lung and colorectal cancer models. SciBrunch had expected the program to enter first-in-human development by the end of 2026. There is, however, no human efficacy or safety evidence yet.
Why It Matters
- KRAS G12D is one of oncology’s most valuable remaining mutation-specific opportunities. It is prevalent across pancreatic, colorectal and lung cancers, while approved KRAS-targeted success has historically concentrated on G12C.
- Merck is purchasing optionality unusually early. A $400 million upfront payment for a preclinical program signals intense competition for differentiated KRAS assets.
- Chinese biotech is becoming an innovation source, not merely a lower-cost development ecosystem. Reuters documented a broader increase in U.S. pharma licensing of Chinese-origin molecules. The SciBrunch agreement is particularly notable because Merck receives worldwide rights.
- The timing intersects directly with Merck’s post-Keytruda challenge. Merck expects U.S. biosimilar competition for Keytruda could begin as early as December 2028.
Healthcare Insight Analysis
Healthcare Insight believes the transaction should not be summarized as “Merck bought a $2.13 billion KRAS drug.”
It did not.
Merck is paying $400 million today for global control of the program’s potential. More than $1.7 billion of additional consideration depends on future development and commercialization milestones.
That structure matters because SPR2015 remains exceptionally early.
The AACR dataset showed tumor regressions in several xenograft models and a reported 64.7% objective response rate across a set of colorectal cancer CDX/PDX models. Those findings justify clinical development, but an ORR in mouse models cannot be translated into an expected human response rate.
The strategic appeal is the RAS(ON) mechanism.
The first successful KRAS inhibitors proved that RAS was not permanently “undruggable.” The next challenge is harder: addressing additional mutations, active-state signaling and resistance mechanisms.
SPR2015 is designed to engage G12D KRAS while it is actively driving proliferative signaling. If that mechanism translates into deep target engagement with an acceptable therapeutic window in humans, the commercial opportunity could span several major tumor types.
This matters particularly in colorectal cancer.
SciBrunch itself notes that existing G12D programs have shown promising clinical activity in pancreatic and lung cancers, while meaningful monotherapy efficacy in CRC remains difficult. That makes colorectal activity a potentially important point of differentiation — but today it exists only in preclinical models.
There is also a broader Merck portfolio story.
Keytruda remains enormously important, while some newer oncology bets have recently faced regulatory setbacks, including the withdrawal of the I-DXd accelerated-approval filing. Merck therefore needs multiple independent shots on goal, not one theoretical replacement for Keytruda.
SPR2015 fits that strategy precisely: early, high-risk, high-upside and mechanistically distinct from immuno-oncology.
The other major signal is where the asset came from.
SciBrunch was founded only in late 2024. Less than two years later, a preclinical program has secured a $400 million upfront global license. That compresses the traditional path from biotech formation to global value realization and illustrates how rapidly Chinese oncology discovery is entering Big Pharma’s business-development pipeline.
Market Implications
Merck: gains another precision-oncology option beyond PD-1, but meaningful de-risking begins only with human safety, PK/PD and early efficacy.
SciBrunch: achieves substantial value creation before Phase 1 and gains access to Merck’s global development infrastructure.
Chinese biotech: growing competition for assets may increase upfront payments and gradually erode the historical “China discount” in licensing economics.
Oncology investors: KRAS remains a high-value field, but valuation must distinguish sharply between preclinical differentiation and clinical validation.
ANALYTICAL MATRIX
| Dimension | Current Position | Opportunity | Key Risk |
| Asset | Preclinical SPR2015 | PDAC, CRC, NSCLC | No human data |
| Economics | $400m upfront; $2.13bn potential | Merck controls global upside | Most value remains milestone-dependent |
| Mechanism | KRAS G12D (ON) molecular glue | Differentiate from earlier KRAS approaches | Human translation unknown |
| Merck strategy | Portfolio diversification | Post-Keytruda growth optionality | Requires multiple clinical successes |
| China biotech | Very early global licensing | Higher global valuations | Increasing competition for assets |
The first two signals to watch are whether SPR2015 enters Phase 1 as planned and demonstrates human target engagement, followed by whether meaningful activity emerges in colorectal cancer, where KRAS-directed monotherapy remains particularly challenging.
If those milestones are achieved, the significance will extend beyond one licensing deal: Big Pharma may increasingly be willing to buy Chinese innovation before clinical proof — not because it is cheaper, but because waiting for proof could mean arriving too late.